accordingly , the results of medicomp , inc. , including the gain recognized on its disposal , have been included in discontinued operations for each of the three years in the three-year period ended december 31 , 2011 on our consolidated statements of operations . refer to note 18  sale of medicomp , inc. to our consolidated financial statements included in this annual report on form 10-k for details . revenues sales of remodulin comprise the largest share of our revenues . other significant sources of revenues include sales of tyvaso and adcirca . sales of tyvaso and adcirca have continued to grow since their commercial introduction in 2009 , as each of these therapies has gained broader market acceptance . we sell remodulin and tyvaso in the united states to our specialty pharmaceutical distributors : accredo health group , inc. , curascript , inc. and cvs caremark . adcirca is sold to pharmaceutical wholesalers that are part of lilly 's pharmaceutical wholesaler network . we also sell remodulin to distributors outside of the united states . on july 21 , 2011 , express scripts , inc. , the parent company of curascript , announced the signing of a merger agreement with medco health solutions , inc. , the parent company of accredo . the parties announced that the merger , which is subject to regulatory and shareholder approvals , is expected to close in the first half of 2012. presently , we do not expect the merger , if approved , to materially affect our business . we require our distributors to maintain reasonable levels of contingent inventory at all times as the interruption of remodulin or tyvaso therapy can be life threatening . consequently , sales of these therapies in any given quarter may not precisely reflect patient demand . our distributors typically place monthly orders based on estimates of future demand and considerations of contractual minimum inventory requirements . as a result , sales volume of remodulin and tyvaso can vary , depending on the timing and magnitude of these orders . the patient protection and affordable care act , as amended by the health care and education reconciliation act ( collectively , the acts ) contains broad provisions that will be implemented over the next several years . we are continually evaluating the impact of the acts on our business ; however , our evaluation is dependent upon the issuance of final regulations and the impact this legislation will have on insurance companies and their relationships with drug manufacturers . on january 1 , 2011 , certain provisions of the acts that address the coverage gap in the medicare part d prescription drug program ( commonly known as the `` donut hole `` ) became effective . under these provisions , drug manufacturers are required to provide a 50 percent discount on branded prescription drugs to patients receiving reimbursement under medicare part d while they remain in this coverage gap . these provisions of the acts apply to adcirca , which is our only commercial pharmaceutical product covered by medicare part d. approximately 35 percent of our adcirca patients are covered under medicare part d. the vast majority of our remodulin and tyvaso medicare patients are covered under medicare part b , which does not contain a similar coverage gap . we were not materially impacted by the acts during 2010 and our revenues were reduced by less than one percent in 2011 as a result of the acts . however , the potential long-term impact of the acts on our business is inherently difficult to predict as many details regarding the implementation of this legislation have not yet been determined . presently , we have not identified any provisions that could 61 materially impact our business , but will continue to monitor future developments related to this legislation . total revenues are reported net of : ( 1 ) estimated rebates ; ( 2 ) prompt pay discounts ; ( 3 ) allowances for product returns or exchanges ; and ( 4 ) distributor fees . we estimate our liability for rebates based on an analysis of historical levels of rebates by product to both state medicaid agencies and commercial third-party payers relative to sales of each product . in addition , we determine our obligation for prescription drug discounts required for medicare part d patients within the coverage gap based on estimations of the number of medicare part d patients and the period such patients will remain within the coverage gap . we provide prompt pay discounts to customers that pay amounts due within a specific time period and base our estimates for prompt pay discounts on observed customer payment behavior . we derive estimates relating to the allowance for returns of adcirca from published industry data specific to specialty pharmaceuticals and will continue to do so until we have sufficient historical data on which to base our allowance . in addition , we compare patient prescription data for adcirca to sales of adcirca on a quarterly basis to ensure a reasonable relationship between prescription and sales trends . to date , we have not identified any unusual patterns in the volume of prescriptions relative to sales that would warrant reconsideration of , or adjustment to , the methodology we currently employ to estimate our allowance for returns . the allowance for exchanges for remodulin is based on the historical rate of product exchanges , which has been too immaterial to record . in addition , because tyvaso is distributed in the same manner and under similar contractual arrangements as remodulin , the level of product exchanges for tyvaso has been comparable to that of remodulin and we anticipate minimal exchange activity in the future for both products . lastly , we estimate distributor fees based on contractual rates for specific services applied to the estimated units of service provided for the period . story_separator_special_tag cancer disease projects ch14.18 antibody in july 2010 , we entered into a cooperative research and development agreement ( crada ) with the national cancer institute ( nci ) to collaborate on the late-stage development and regulatory submissions of chimeric monoclonal antibody 14.18 ( ch14.18 ) for children with high-risk neuroblastoma and patients with other forms of cancer . ch14.18 is an antibody that has shown potential in the treatment of certain types of cancer by targeting gd2 , a glycolipid on the surface of tumor cells . under the terms of the crada , nci is conducting a clinical trial in approximately 100 patients to define more clearly the safety and toxicity profile of ch14.18 immunotherapy in children , and we are developing the commercial manufacturing capability for the antibody . as part of developing our commercial manufacturing capability , we will need to demonstrate comparability of our ch14.18 to the nci-produced ch14.18 , which typically includes a series of analytical and bioanalytical assays and human pharmacokinetics . the nci studies , including a previously conducted phase iii clinical trial and all other necessary studies supported by nci , will be used as the basis for a biologics license application we expect to file seeking fda approval of ch14.18 immunotherapy for the treatment of neuroblastoma . we have received orphan drug designation for ch14.18 from the fda and european medicines agency . 66 8h9 antibody pursuant to a december 2007 agreement with memorial sloan-kettering cancer center , we obtained certain license rights to an investigational monoclonal antibody , 8h9 , for the treatment of metastatic brain cancer . 8h9 is a mouse igg1 mab that is highly reactive with a range of human solid tumors , including human brain cancers . the 8h9 antibody is in early investigational development for metastases that develop in the brain from the spread of cancers from other tissues in the body . metastatic brain cancers are ten times more common than cancers that originate in the brain , and prognosis for patients with metastatic brain cancers is very poor . in the united states , more than 100,000 cases of metastatic brain cancer are diagnosed each year . we have spent $ 75.0 million from inception to december 31 , 2011 , on our cancer programs . infectious disease projects pursuant to our research agreement with the university of oxford ( oxford ) , we have the exclusive right to commercialize a platform of glycobiology antiviral drug candidates in various preclinical and clinical stages of testing for the treatment of a wide variety of viruses . through our research agreement with oxford , we are also supporting research into new glycobiology antiviral drug candidates and technologies . we are currently testing many of these compounds in preclinical studies and oxford continues to synthesize new agents that we may elect to test . on september 30 , 2011 , we were awarded a cost plus fixed fee contract with an aggregate value of up to $ 45.0 million under a broad agency announcement from the u.s. national institute of allergy and infectious diseases for studies directed at the development of a broad spectrum antiviral drug based on our glycobiology antiviral platform . under the contract 's base period of forty-two months , we will receive $ 10.6 million in funding and there are eight milestone-based options to expand the project and funding under the contract , up to an aggregate of $ 45.0 million . we recognize revenue on this contract to the extent of costs incurred , plus a proportionate amount of fees earned . we have spent $ 52.6 million from inception to december 31 , 2011 , on our infectious disease programs . future prospects because pah remains a progressive disease without a cure , we expect continued growth in the demand for our commercial products as alternatives or complements to other existing approved therapies . furthermore , the commercial introduction of tyvaso and adcirca has enabled us to offer products to more patients along the full continuum of the disease . the continued achievement of our growth objectives will depend in large part upon the successful commercial development of products within our pipeline . to this end , we submitted to the fda an nda for oral treprostinil in december 2011 , plan to initiate enrollment in the freedom-c 3 study of oral treprostinil and a new event-driven phase iii tyvaso study during 2012 and continue to develop beraprost-mr. in addition , we seek to expand the use of our therapies to treat patients at earlier stages in the pah disease progression . our future growth and profitability will depend on many factors including , but not limited to : ( 1 ) the timing and outcome of clinical trials and regulatory approvals , including the filing and approval of our nda for oral treprostinil , and the pmr for tyvaso ; ( 2 ) the timing of the commercial launch of new products ; ( 3 ) the pricing of and demand for our products and services ; ( 4 ) the reimbursement of our products by public and private insurance organizations ; ( 5 ) the competition we face within our industry ; ( 6 ) our ability to effectively manage our growth in an increasingly complex regulatory environment ; and ( 7 ) our ability to defend against generic competition , including the recent challenge to our remodulin patents by a generic drug company . 67 we operate in a highly competitive market in which a small number of pharmaceutical companies control a majority of the currently approved pah therapies . these pharmaceutical companies not only possess greater visibility in the market , but also greater financial , technical and marketing resources than we do . in addition , there are a number of investigational products in late-stage development that , if approved , may erode the market share of our existing commercial therapies and make market

debt to the consolidated financial statements included in this annual report on form 10-k for details . other noncurrent liabilities at december 31 , 2011 were $ 80.5 million , compared to $ 39.3 million at december 31 , 2010. the $ 41.2 million increase was largely due to the recognition of the net , non-current portion of our royalty buy-down obligation to toray in the amount of $ 28.3 million and a $ 6.5 million increase in our supplemental executive retirement plan ( serp ) obligation which reflects an increased number of serp participants . additional paid-in capital increased by $ 64.0 million from $ 928.7 million at december 31 , 2010 to $ 992.7 million at december 31 , 2011. the increase consisted principally of the following elements : ( 1 ) increases of $ 24.0 million and $ 11.3 million , respectively , relating to proceeds received from stock-option exercises and related tax benefits ; ( 2 ) an increase of $ 27.3 million recognized in connection with the value of the shares we received from the exercise of a note hedge upon the conversion of the 2011 convertible notes ; and ( 3 ) an increase of $ 27.1 million representing the net effects of the issuance of the 2016 convertible notes and related note hedge and warrant transactions .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```debt to the consolidated financial statements included in this annual report on form 10-k for details . other noncurrent liabilities at december 31 , 2011 were $ 80.5 million , compared to $ 39.3 million at december 31 , 2010. the $ 41.2 million increase was largely due to the recognition of the net , non-current portion of our royalty buy-down obligation to toray in the amount of $ 28.3 million and a $ 6.5 million increase in our supplemental executive retirement plan ( serp ) obligation which reflects an increased number of serp participants . additional paid-in capital increased by $ 64.0 million from $ 928.7 million at december 31 , 2010 to $ 992.7 million at december 31 , 2011. the increase consisted principally of the following elements : ( 1 ) increases of $ 24.0 million and $ 11.3 million , respectively , relating to proceeds received from stock-option exercises and related tax benefits ; ( 2 ) an increase of $ 27.3 million recognized in connection with the value of the shares we received from the exercise of a note hedge upon the conversion of the 2011 convertible notes ; and ( 3 ) an increase of $ 27.1 million representing the net effects of the issuance of the 2016 convertible notes and related note hedge and warrant transactions .
```    
 Suspicious Activity Report : accordingly , the results of medicomp , inc. , including the gain recognized on its disposal , have been included in discontinued operations for each of the three years in the three-year period ended december 31 , 2011 on our consolidated statements of operations . refer to note 18  sale of medicomp , inc. to our consolidated financial statements included in this annual report on form 10-k for details . revenues sales of remodulin comprise the largest share of our revenues . other significant sources of revenues include sales of tyvaso and adcirca . sales of tyvaso and adcirca have continued to grow since their commercial introduction in 2009 , as each of these therapies has gained broader market acceptance . we sell remodulin and tyvaso in the united states to our specialty pharmaceutical distributors : accredo health group , inc. , curascript , inc. and cvs caremark . adcirca is sold to pharmaceutical wholesalers that are part of lilly 's pharmaceutical wholesaler network . we also sell remodulin to distributors outside of the united states . on july 21 , 2011 , express scripts , inc. , the parent company of curascript , announced the signing of a merger agreement with medco health solutions , inc. , the parent company of accredo . the parties announced that the merger , which is subject to regulatory and shareholder approvals , is expected to close in the first half of 2012. presently , we do not expect the merger , if approved , to materially affect our business . we require our distributors to maintain reasonable levels of contingent inventory at all times as the interruption of remodulin or tyvaso therapy can be life threatening . consequently , sales of these therapies in any given quarter may not precisely reflect patient demand . our distributors typically place monthly orders based on estimates of future demand and considerations of contractual minimum inventory requirements . as a result , sales volume of remodulin and tyvaso can vary , depending on the timing and magnitude of these orders . the patient protection and affordable care act , as amended by the health care and education reconciliation act ( collectively , the acts ) contains broad provisions that will be implemented over the next several years . we are continually evaluating the impact of the acts on our business ; however , our evaluation is dependent upon the issuance of final regulations and the impact this legislation will have on insurance companies and their relationships with drug manufacturers . on january 1 , 2011 , certain provisions of the acts that address the coverage gap in the medicare part d prescription drug program ( commonly known as the `` donut hole `` ) became effective . under these provisions , drug manufacturers are required to provide a 50 percent discount on branded prescription drugs to patients receiving reimbursement under medicare part d while they remain in this coverage gap . these provisions of the acts apply to adcirca , which is our only commercial pharmaceutical product covered by medicare part d. approximately 35 percent of our adcirca patients are covered under medicare part d. the vast majority of our remodulin and tyvaso medicare patients are covered under medicare part b , which does not contain a similar coverage gap . we were not materially impacted by the acts during 2010 and our revenues were reduced by less than one percent in 2011 as a result of the acts . however , the potential long-term impact of the acts on our business is inherently difficult to predict as many details regarding the implementation of this legislation have not yet been determined . presently , we have not identified any provisions that could 61 materially impact our business , but will continue to monitor future developments related to this legislation . total revenues are reported net of : ( 1 ) estimated rebates ; ( 2 ) prompt pay discounts ; ( 3 ) allowances for product returns or exchanges ; and ( 4 ) distributor fees . we estimate our liability for rebates based on an analysis of historical levels of rebates by product to both state medicaid agencies and commercial third-party payers relative to sales of each product . in addition , we determine our obligation for prescription drug discounts required for medicare part d patients within the coverage gap based on estimations of the number of medicare part d patients and the period such patients will remain within the coverage gap . we provide prompt pay discounts to customers that pay amounts due within a specific time period and base our estimates for prompt pay discounts on observed customer payment behavior . we derive estimates relating to the allowance for returns of adcirca from published industry data specific to specialty pharmaceuticals and will continue to do so until we have sufficient historical data on which to base our allowance . in addition , we compare patient prescription data for adcirca to sales of adcirca on a quarterly basis to ensure a reasonable relationship between prescription and sales trends . to date , we have not identified any unusual patterns in the volume of prescriptions relative to sales that would warrant reconsideration of , or adjustment to , the methodology we currently employ to estimate our allowance for returns . the allowance for exchanges for remodulin is based on the historical rate of product exchanges , which has been too immaterial to record . in addition , because tyvaso is distributed in the same manner and under similar contractual arrangements as remodulin , the level of product exchanges for tyvaso has been comparable to that of remodulin and we anticipate minimal exchange activity in the future for both products . lastly , we estimate distributor fees based on contractual rates for specific services applied to the estimated units of service provided for the period . story_separator_special_tag cancer disease projects ch14.18 antibody in july 2010 , we entered into a cooperative research and development agreement ( crada ) with the national cancer institute ( nci ) to collaborate on the late-stage development and regulatory submissions of chimeric monoclonal antibody 14.18 ( ch14.18 ) for children with high-risk neuroblastoma and patients with other forms of cancer . ch14.18 is an antibody that has shown potential in the treatment of certain types of cancer by targeting gd2 , a glycolipid on the surface of tumor cells . under the terms of the crada , nci is conducting a clinical trial in approximately 100 patients to define more clearly the safety and toxicity profile of ch14.18 immunotherapy in children , and we are developing the commercial manufacturing capability for the antibody . as part of developing our commercial manufacturing capability , we will need to demonstrate comparability of our ch14.18 to the nci-produced ch14.18 , which typically includes a series of analytical and bioanalytical assays and human pharmacokinetics . the nci studies , including a previously conducted phase iii clinical trial and all other necessary studies supported by nci , will be used as the basis for a biologics license application we expect to file seeking fda approval of ch14.18 immunotherapy for the treatment of neuroblastoma . we have received orphan drug designation for ch14.18 from the fda and european medicines agency . 66 8h9 antibody pursuant to a december 2007 agreement with memorial sloan-kettering cancer center , we obtained certain license rights to an investigational monoclonal antibody , 8h9 , for the treatment of metastatic brain cancer . 8h9 is a mouse igg1 mab that is highly reactive with a range of human solid tumors , including human brain cancers . the 8h9 antibody is in early investigational development for metastases that develop in the brain from the spread of cancers from other tissues in the body . metastatic brain cancers are ten times more common than cancers that originate in the brain , and prognosis for patients with metastatic brain cancers is very poor . in the united states , more than 100,000 cases of metastatic brain cancer are diagnosed each year . we have spent $ 75.0 million from inception to december 31 , 2011 , on our cancer programs . infectious disease projects pursuant to our research agreement with the university of oxford ( oxford ) , we have the exclusive right to commercialize a platform of glycobiology antiviral drug candidates in various preclinical and clinical stages of testing for the treatment of a wide variety of viruses . through our research agreement with oxford , we are also supporting research into new glycobiology antiviral drug candidates and technologies . we are currently testing many of these compounds in preclinical studies and oxford continues to synthesize new agents that we may elect to test . on september 30 , 2011 , we were awarded a cost plus fixed fee contract with an aggregate value of up to $ 45.0 million under a broad agency announcement from the u.s. national institute of allergy and infectious diseases for studies directed at the development of a broad spectrum antiviral drug based on our glycobiology antiviral platform . under the contract 's base period of forty-two months , we will receive $ 10.6 million in funding and there are eight milestone-based options to expand the project and funding under the contract , up to an aggregate of $ 45.0 million . we recognize revenue on this contract to the extent of costs incurred , plus a proportionate amount of fees earned . we have spent $ 52.6 million from inception to december 31 , 2011 , on our infectious disease programs . future prospects because pah remains a progressive disease without a cure , we expect continued growth in the demand for our commercial products as alternatives or complements to other existing approved therapies . furthermore , the commercial introduction of tyvaso and adcirca has enabled us to offer products to more patients along the full continuum of the disease . the continued achievement of our growth objectives will depend in large part upon the successful commercial development of products within our pipeline . to this end , we submitted to the fda an nda for oral treprostinil in december 2011 , plan to initiate enrollment in the freedom-c 3 study of oral treprostinil and a new event-driven phase iii tyvaso study during 2012 and continue to develop beraprost-mr. in addition , we seek to expand the use of our therapies to treat patients at earlier stages in the pah disease progression . our future growth and profitability will depend on many factors including , but not limited to : ( 1 ) the timing and outcome of clinical trials and regulatory approvals , including the filing and approval of our nda for oral treprostinil , and the pmr for tyvaso ; ( 2 ) the timing of the commercial launch of new products ; ( 3 ) the pricing of and demand for our products and services ; ( 4 ) the reimbursement of our products by public and private insurance organizations ; ( 5 ) the competition we face within our industry ; ( 6 ) our ability to effectively manage our growth in an increasingly complex regulatory environment ; and ( 7 ) our ability to defend against generic competition , including the recent challenge to our remodulin patents by a generic drug company . 67 we operate in a highly competitive market in which a small number of pharmaceutical companies control a majority of the currently approved pah therapies . these pharmaceutical companies not only possess greater visibility in the market , but also greater financial , technical and marketing resources than we do . in addition , there are a number of investigational products in late-stage development that , if approved , may erode the market share of our existing commercial therapies and make market

